Article

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML

2024-01-30

Abstract excerpt

The venetoclax BCL2 inhibitor in combination with hypomethylating agents represents a cornerstone of induction therapy for older AML patients, unfit for intensive chemotherapy. Like other targeted therapies, venetoclax-based therapies suffer from innate and acquired resistance. While several mechanisms of resistance have been identified, the heterogeneity of resistance mechanism across patient populations is poorl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9760bb4a-097e-5c1a-b783-d98d90fa5ed3
DOI: 10.1101/2024.01.27.577579

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLDOI 10.1101/2024.01.27.577579Read

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity Read

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaSemantic proximity Read

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read

Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapySemantic proximity Read

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaSemantic proximity Read

Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity Read

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.Semantic proximity Read

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity Read

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.Semantic proximity Read

The Spectrum of Venetoclax-Based Treatments in Acute Myeloid LeukemiaSemantic proximity Read

Venetoclax resistance: mechanistic insights and future strategiesSemantic proximity Read